Why Regulatory Uncertainty Is Becoming the Biggest Barrier to AI in Clinical Trials
Clinical trial experts report that trust and regulatory uncertainty remain the main barriers to full AI adoption in clinical research. The Pistoia Alliance conducted this survey at CTTC in London, where specialists discussed real-world implementation challenges.
Although AI already supports several clinical development areas, concerns around compliance clarity and system reliability still limit wider deployment. Therefore, the industry continues to move cautiously, especially when patient safety and regulatory accountability are involved.
Early AI ROI Emerges in Clinical Trials, but Industry Adoption Still Stays Fragmented
The survey shows that AI already generates value in clinical trials. About 42% of respondents report early signs of ROI, while 23% expect ROI but have not achieved it yet.
Moreover, experts expect AI to have the strongest impact over the next three to five years in data cleaning, analysis, and insight generation, which accounts for 48% of responses. In addition, 22% highlight patient sourcing and engagement as key future applications.
Although progress is visible, adoption remains uneven across the industry.
Real-World Data and Social Listening Quietly Reshape Clinical Trial Decision-Making
The survey highlights a growing shift toward real-world and patient-generated data in clinical research. Around 60% of respondents already use or explore this data to support clinical development decisions beyond traditional marketing.
Furthermore, 58% say social media listening helps them better understand patient needs, sentiment, and experience. This shift reflects a broader move toward data-driven decision-making beyond controlled trial settings.
Regulators Signal a Shift: Explainable AI Becomes a New Compliance Expectation in Pharma
Dr Becky Upton, President of the Pistoia Alliance, notes that regulators are ready to engage with AI but emphasize early collaboration to ensure safe adoption. She stresses that speed alone is not enough when patient safety is at stake. Therefore, the industry needs validated, auditable, and explainable AI systems instead of black-box models that create uncertainty.
FDA and EMA Move Toward Formal AI Guidelines for Clinical and Drug Development Decisions
Regulatory agencies are gradually shaping expectations for AI in drug development. The FDA issued guidance in January 2025 on using AI for regulatory decision-making in drug and biological products. Similarly, the EMA released a reflection paper on AI in the medicinal product lifecycle, linking it to GCP and ICH standards.
Pharma AI Future: Efficiency Gains vs Trust and Compliance Risks
GlobalData reports that AI could reduce pharmaceutical R&D costs by improving drug discovery and clinical trial efficiency. Although adoption remains stronger in preclinical stages, a portion of experts already see AI becoming a key driver across both preclinical and clinical development in the near term.
AI in Clinical Trials Under Pressure: Trust Issues and Regulatory Uncertainty Escalate
The survey highlights a clear tension in the industry. AI delivers measurable gains, yet trust issues and regulatory uncertainty still slow full adoption. Therefore, the future of AI in clinical trials depends on explainable systems that align with global compliance and regulatory expectations.
As AI expands in clinical trials, regulatory uncertainty is increasing the need for strong validation and compliance in GxP systems. Without proper control, AI tools may create inspection and data integrity risks.
Qualification and Validation for GMP-Regulated Systems helps pharmaceutical teams ensure their digital and AI-enabled systems remain compliant, validated, and inspection-ready across the full lifecycle.
Source: Clinicaltrialsarena.Com